NexImmune, Inc.: Nasdaq/NYSE listing notice — NexImmune regains Nasdaq minimum bid price compliance; delisting notice resolved

NexImmune, Inc.

Received delisting notice on Oct 27, 2023 after second 180-day compliance period expired Oct 23.
Regained compliance per Nasdaq notice dated Nov 1, 2023 following 1-for-25 reverse stock split effective Oct 18.
Closing bid price has remained above $1.00 since reverse split; Nasdaq listing matter closed.
Common stock continues trading on Nasdaq Capital Market under ticker NEXI.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

NexImmune, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: compliance regained
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

November 1, 2023, NexImmune, Inc. (the “Company”) received a notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market (the “Capital Market”) under Nasdaq Listing Rule 5550(a)(2) (the “Rule”), and as a result, the Company’s common stock continues to trade on the Capital Market and the matter is now closed. Previously, on October 27, 2023, the Company received a notice from Nasdaq informing the Company that Nasd

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-269417

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.